CL Stock Overview

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More details

CL fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 72.7% below our estimate of its fair value

Trading at good value compared to peers and industry

Risk Analysis

Volatile share price over the past 3 months compared to the Canadian market

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Cresco Labs Inc. Competitors

Knight Therapeutics

TSX:GUD

CA$538.3m

Verano Holdings

NEOE:VRNO

CA$617.0m

Cipher Pharmaceuticals

TSX:CPH

CA$367.7m

Canopy Growth

TSX:WEED

CA$423.5m

Price History & Performance

Summary of share price highs, lows and changes for Cresco Labs
Historical stock prices
Current Share Price	CA$1.20
52 Week High	CA$3.58
52 Week Low	CA$1.17
Beta	1.92
1 Month Change	-27.27%
3 Month Change	-45.95%
1 Year Change	-32.96%
3 Year Change	-85.70%
5 Year Change	-85.38%
Change since IPO	-81.68%

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Dec 14

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24

Recent updates

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Dec 14

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Shareholder Returns

	CL	CA Pharmaceuticals	CA Market
7D	-4.0%	-1.0%	0.9%
1Y	-33.0%	-31.4%	15.7%

Return vs Industry: CL underperformed the Canadian Pharmaceuticals industry which returned -31.4% over the past year.

Return vs Market: CL underperformed the Canadian Market which returned 15.7% over the past year.

Price Volatility

Is CL's price volatile compared to industry and market?
CL volatility
CL Average Weekly Movement	13.3%
Pharmaceuticals Industry Average Movement	12.1%
Market Average Movement	8.1%
10% most volatile stocks in CA Market	17.3%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: CL's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: CL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

Founded	Employees	CEO	Website
1990	3,000	Charlie Bachtell	www.crescolabs.com

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy’s Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts.

Cresco Labs Inc. Fundamentals Summary

How do Cresco Labs's earnings and revenue compare to its market cap?
CL fundamental statistics
Market cap	CA$529.96m
Earnings (TTM)	-CA$97.21m
Revenue (TTM)	CA$1.05b

0.4x

P/S Ratio

-4.3x

P/E Ratio

Is CL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CL income statement (TTM)
Revenue	US$726.35m
Cost of Revenue	US$360.10m
Gross Profit	US$366.26m
Other Expenses	US$433.69m
Earnings	-US$67.43m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.19
Gross Margin	50.42%
Net Profit Margin	-9.28%
Debt/Equity Ratio	116.3%

How did CL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 21:58
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cresco Labs Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aaron Grey	Alliance Global Partners
Frederico Yokota Choucair Gomes	ATB Capital Markets
Kenric Tyghe	ATB Capital Markets

CL Stock Overview

Rewards

Risk Analysis

Cresco Labs Inc. Competitors

TSX:GUD

CA$538.3m

NEOE:VRNO

CA$617.0m

TSX:CPH

CA$367.7m

TSX:WEED

CA$423.5m

Price History & Performance

Recent News & Updates

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Consensus EPS estimates fall by 35%

New minor risk - Share price stability

No longer forecast to breakeven

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Recent updates

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Consensus EPS estimates fall by 35%

New minor risk - Share price stability

No longer forecast to breakeven

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024

Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Co-Founder & Independent Director recently sold CA$110k worth of stock

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors